Reduction of tamoxifen resistance in human breast carcinomas by tamoxifen-containing liposomes in vivo

Anti-Cancer Drugs

Volumn 15, Issue 7, 2004, Pages 707-714

  Zeisig, Reiner ^a   Rückerl, Dominik ^b   Fichtner, Iduna ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Breast cancer; Liposome; Pharmacokinetics; Resistance; Tamoxifen; Xenograft

Indexed keywords

ANTIESTROGEN; LIPOSOME; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER MODEL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; LIPOSOMES; MICE; NEOPLASM TRANSPLANTATION; ORGAN SIZE; TAMOXIFEN; UTERUS;

EID: 4143072458     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000136885.65293.e9     Document Type: Article

References (40)

1. Gajdos C, Jordan VC. Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade. Clin Breast Cancer 2002; 2:272-281.
2. Jordan VC. Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. J Natl Cancer Inst 1998; 90:967-971.
3. Favoni RE, de Cupis A. Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal. Trends Pharmacol Sci 1998; 19:406-415.
4. Greenberger LM, Annable T, Collins KI, Komm BS, Lyttle C R, Miller CP, et al. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl- ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats. Clin Cancer Res 2001; 7:3166-3177.
5. Gradishar WJ, Jordan VC. Clinical potential of new antiestrogens. J Clin Oncol 1997; 15:840-852.
6. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002; 54:631-651.
7. Arndt D, Zeisig R, Bechtel D, Fichtner I. Liposomal bleomycin: increased therapeutic activity and decreased pulmonary toxicity in mice. Drug Deliv 2001; 8:1-7.
8. Sadzuka Y, Hirotsu S, Hirota S. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. Cancer Lett 1998; 127:99-106.
9. Lasic DD, Papahadjopoulos D. Medical Application of Liposomes. Amsterdam: Elsevier Science; 1998.
10. Zeisig R, Arndt D, Stahn R, Fichtner I. Physical properties and pharmacological activity in vitro and in vivo of optimized liposomes prepared from a new cancerostatic alkylphospholipid. Biochim Biophys Acta 1998; 1414:238-248.
11. Arndt D, Zeisig R, Fichtner I, Teppke AD, Fahr A. Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice. Breast Cancer Res Treat 1999; 58:71-80.
12. Chan S. A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer. Semin Oncol 2002; 29:129-133.
13. Chew HK. Medical management of breast cancer: today and tomorrow. Cancer Biother Radiopharm 2002; 17:137-149.
14. Clemons M, Danson S, Howell A. Tamoxifen ('Nolvadex'): a review. Cancer Treat Rev 2002; 28:165-180.
15. Jordan C. Historical perspective on hormonal therapy of advanced breast cancer. Clin Ther 2002; 24(suppl A):A3-A16.
16. Katzenellenbogen BS. Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol Reprod 1996; 54:287-293.
17. Johnston SR. Acquired tamoxifen resistance in human breast cancer - potential mechanisms and clinical implications. Anticancer Drugs 1997; 8:911-930.
18. Katzenellenbogen BS, Montano MM, Ekena K, Herman ME, McInerney EM, William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat 1997; 44:23-38.
19. Levenson AS, Jordan VC. Selective oestrogen receptor modulation: molecular pharmacology for the millennium. Eur J Cancer 1999; 35:1628-1639.
20. Hamilton A, Piccart M. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 1999; 10:377-384.
21. Braun M. Has tamoxifen had its time? Breast Cancer Res 2002; 4:213-217.
22. Arndt D, Zeisig R, Fichtner I. Alkylphospholipid liposomes: preparation, properties and use in cancer research. 1998; 34(suppl F):83-96.
23. Fichtner I, Reszka R, Goan SR, Naundorf H. Carboplatin-liposomes (CPL) in immunodeficient mice: improved antitumor activity for breast carcinomas and stimulation of hematopoiesis. Med Oncol 1994; 11:111-119.
24. Sadzuka Y, Hirotsu S, Hirota S. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. Cancer Lett 1998; 127:99-106.
25. Dass CR, Su T. Particle-mediated intravascular delivery of oligonucleotides to tumors: associated biology and lessons from genotherapy. Drug Deliv 2001; 8:191-213.
26. Torchilin VP. Drug targeting. Eur J Pharm Sci 2000; 11 (suppl 2):S81-S91.
27. Storch J, Munder PG. Increased membrane permeability for an antitumoral alkyl lysophospholipid in sensitive tumor cells. Lipids 1987; 22:813-819.
28. Fichtner I, Naundorf H, Saul GJ, Zschiesche W, Zeisig R. Establishment and characterization of human xenotransplanted breast carcinoma lines: use for the screening of alkylphosphocholines (APC). In: Arnold W, Köpf-Maier P, Micheel B (editors): Immunodeficient Animals: Models for Cancer Research. Basel: Karger; 1996, pp. 129-133.
29. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 1991; 19:36-43.
30. Daemen T, Velinova M, Regts J, de Jager M, Kalicharan R, Donga J, et al. Different intrahepatic distribution of phosphatidylglycerol and phosphatidylserine liposomes in the rat. Hepatology 1997; 26:416-423.
31. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 1994; 15:215-220.
32. Wiseman H, Cannon M, Arnstein HR, Barlow DJ. The structural mimicry of membrane sterols by tamoxifen: evidence from cholesterol coefficients and molecular-modelling for its action as a membrane anti-oxidant and an anticancer agent. Biochim Biophys Acta 1992; 1138:197-202.
33. Zeisig R, Müller K, Maurer N, Arndt D, Fahr A. The composition-dependent presence of free (micellar) alkylphospholipid in liposomal formulations of octadecyl-1,1-dimethyl-piperidino-4-yl-phosphate affects its cytotoxic activity in vitro. J Membr Biol 2001; 182:61-69.
34. Zeisig R, Stahn R, Teppke AD, Arndt D. Cancerostatic octadecylpiperidinoylphosphate liposomes: effect of composition on uptake by and toxicity to J774 mouse macrophage cells and MT1 breast cancer cells in vitro. Anticancer Drug Des 2001; 16:19-26.
35. Allen TM, Austin GA, Chonn A, Lin L, Lee KC. Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. Biochim Biophys Acta 1991; 1061:56-64.
36. Naundorf H, Fichtner I, Büttner B, Frege J. Establishment and characterization of a new human estradiol- and progesterone-receptor-positive mammary carcinoma serially transplantable in nude mice. J Cancer Res Clin Oncol 1992; 119:35-40.
37. Naundorf H, Becker M, Lykkesfeldt AE, Elbe B, Neumann C, Büttner B, Fichtner I. Development and characterization of a tamoxifen-resistant breast carcinoma xenograft. Br J Cancer 2000; 82:1844-1850.
38. Kubota T, Kubouchi K, Koh J, Enomoto K, Ishibiki K, Abe O. Human breast carcinoma (MCF-7) serially transplanted into nude mice. Jpn J Surg 1983; 13:381-384.
39. Massazza G, Tomasoni A, Lucchini V, Allavena P, Erba E, Colombo N, et al. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int J Cancer 1989; 44:494-500.
40. Dykes DJ, Bissery MC, Harrison Jr SD, Waud WR. Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Invest New Drugs 1995; 13:1-11.